Mark is CTO & Co-Founder of Quench Bio and an Entrepreneur-in-Residence at Atlas Venture. Formerly Mark was VP, Head of Drug Discovery at Quartet Medicine. Mark has over 23 years of experience in drug discovery and development and is a co-inventor of Incivek (Telaprevir), an HCV protease inhibitor. He was previously VP of Medicinal and Computational Chemistry at Forma Therapeutics, where he focused on small molecule cancer therapeutics. Prior to that, Mark held positions of increasing responsibility during his 16-year career at Eli Lilly including head of chemistry and Global Head of Operations for the discovery chemistry group. He obtained his PhD in organic chemistry from Stanford University and his undergraduate degree from the University of Notre Dame. Outside of work, Mark enjoys running, biking and eating things that are really sweet or extremely hot.